12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

• Cumberland (NASDAQ:CPIX) stock rose 30.3% to $2.15 during Monday's pre-market session. The market value of their outstanding shares is at $30.9 million. As per the press release, Q1 earnings came out 4 days ago.
• Aligos Therapeutics (NASDAQ:ALGS) shares increased by 27.52% to $1.39. The market value of their outstanding shares is at $59.6 million.
• Sarepta Therapeutics (NASDAQ:SRPT) stock increased by 25.87% to $151.3. The company's market cap stands at $14.0 billion.
• CEL-SCI (AMEX:CVM) stock moved upwards by 15.41% to $2.77. The market value of their outstanding shares is at $123.4 million. As per the news, the Q2 earnings report came out yesterday.
• Cadrenal Therapeutics (NASDAQ:CVKD) shares rose 14.12% to $1.6. The company's market cap stands at $18.5 million.
• Tivic Health Systems (NASDAQ:TIVC) shares increased by 13.49% to $0.2. The market value of their outstanding shares is at $5.9 million. As per the news, the Q1 earnings report came out today.

Losers

• Athenex (NASDAQ:ATNX) stock declined by 53.5% to $0.53 during Monday's pre-market session. The market value of their outstanding shares is at $4.5 million.
• Larimar Therapeutics (NASDAQ:LRMR) stock declined by 20.95% to $4.0. The market value of their outstanding shares is at $173.0 million.
• NovaBay Pharmaceuticals (AMEX:NBY) stock declined by 20.07% to $0.78. The market value of their outstanding shares is at $1.5 million. The company's, Q1 earnings came out 2 days ago.
• Dermata Therapeutics (NASDAQ:DRMA) shares fell 11.88% to $2.3. The market value of their outstanding shares is at $1.9 million. As per the press release, Q1 earnings came out 2 days ago.
• Meihua Intl Medical Techs (NASDAQ:MHUA) stock decreased by 11.43% to $3.72. The market value of their outstanding shares is at $89.0 million.
• Genelux (NASDAQ:GNLX) shares decreased by 9.81% to $23.0. The company's market cap stands at $564.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.